LYRA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Lyra Therapeutics Inc (LYRA) is not a good buy at this time for a beginner investor seeking long-term growth. The technical indicators are bearish, the financial performance is weak, and there are no positive catalysts or significant trading trends to support a buy decision. Additionally, the lack of recent news, analyst ratings, or influential trading activity further diminishes the stock's appeal.
The technical indicators for LYRA are bearish. The MACD histogram is negative and expanding downward, the RSI is neutral at 21.169, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest the stock is trading near its support (S1: 1.409, current price: 1.32), with further downside risk.
NULL. There are no recent news events, trading trends, or influential trading activity to act as a positive catalyst.
Weak financial performance in Q3 2025, with revenue dropping by -87.18% YoY, net income declining by -49.60% YoY, and EPS falling by -62.73% YoY. Additionally, the stock's technical indicators are bearish, and there is no significant trading sentiment or analyst support.
In Q3 2025, Lyra Therapeutics reported a significant decline in financial performance. Revenue dropped to $25,000 (-87.18% YoY), net income fell to -$5,984,000 (-49.60% YoY), and EPS decreased to -3.38 (-62.73% YoY). Gross margin remained at 100%, but this is overshadowed by the overall poor financial results.
No recent analyst ratings or price target changes are available for LYRA.
